<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="32">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 14, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658277</url>
  </required_header>
  <id_info>
    <org_study_id>Macrolid/Bronchiectasis/2019</org_study_id>
    <nct_id>NCT04658277</nct_id>
  </id_info>
  <brief_title>Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations</brief_title>
  <official_title>Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      clarithromycin may reduce the exacerbations in middle-aged and elderly patients with non-CF&#xD;
      bronchiectasis.&#xD;
&#xD;
      The study is aimed to (A) investigate the etiologies and clinical features of patients with&#xD;
      bronchiectasis, (B) compare the effect of clarithromycin 250mg daily on the frequency of&#xD;
      exacerbations, quality of life and lung function, stratified according to the degree of&#xD;
      bronchiectasis severity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of infectious exacerbations</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first exacerbation (Days)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of symptom-based exacerbations (number of events per month)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of post bronchodilator Forced Expiratory volume in 1 sec and forced vital capacity</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of exercise capacity (flights of stairs)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of St George Respiratory Questionnaire Score</measure>
    <time_frame>26 weeks</time_frame>
    <description>Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of concentration of serum c-reactive protein (mg/L)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be given one tab of Clarithromycin 250mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive usual medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Patients in the intervention arm will take Clarithromycin 250mg daily.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Patients will receive usual medical care</description>
    <arm_group_label>usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 50 years or older&#xD;
&#xD;
          -  At least 2 or more exacerbation requiring antibiotic treatment in the past year&#xD;
             Clinically stable for at least 4 weeks prior to enrollment (defined as no symptoms of&#xD;
             exacerbation, no requirement for supplemental antibiotic therapy)&#xD;
&#xD;
          -  Diagnosis of bronchiectasis defined by high-resolution computed tomography (CT) scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cystic fibrosis; hypogammaglobulinemia; allergic bronchopulmonary&#xD;
             aspergilosis,&#xD;
&#xD;
          -  Cigarette smoking within 6 months&#xD;
&#xD;
          -  A positive culture of non-tuberculosis mycobacteria in the past 2 years or at&#xD;
             screening&#xD;
&#xD;
          -  Macrolide treatment for more than 3 months in the past 6 months&#xD;
&#xD;
          -  Oral or intravenous courses of corticosteroids within 30 days of screening&#xD;
&#xD;
          -  Any antimicrobial treatment for lower respiratory tract infection in the last 2 weeks&#xD;
&#xD;
          -  Unstable arrhythmia&#xD;
&#xD;
          -  History of coronary artery disease, or symptoms of heart disease&#xD;
&#xD;
          -  Known allergy or intolerance to macrolides&#xD;
&#xD;
          -  Patients with liver disease or with elevated transaminanse (aspartate aminotransferase&#xD;
             (AST) and alanine aminotransferase (ALT) levels equal to or greater than the upper&#xD;
             limit of the normal)&#xD;
&#xD;
          -  Concurrent medication: Colchicine, calcium channel blocker, statins, amiodarone,&#xD;
             amitriptyline, trazodone, citalopram, disopyramide, itraconazole, saquinavir,&#xD;
             ritaonavir, atazanavir, sildenafil, tadalafil, vardenafil, theophylline,&#xD;
             carbamazepine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chinese University of Hong</name>
      <address>
        <city>Hong Kong</city>
        <state>Please Select</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna SS Ng, MBChB</last_name>
      <phone>(852) 35053493</phone>
      <email>ssng@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Susanna SS Ng</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

